Clinical Trial: QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07903636) titled 'QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease' on Oct. 23.

Brief Summary: This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD).

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: DRUG: QLS4131

Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 w...